Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Gain Therapeutics's total debt was $343.69K at Jun 30, 2026. For fiscal 2025 it was $400.95K, down 8.6% from the year before. The highest annual figure on record is $738.28K in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.95K | -8.6% |
| FY2024 | Dec 31, 2024 | $438.50K | -22.8% |
| FY2023 | Dec 31, 2023 | $567.85K | -5.9% |
| FY2022 | Dec 31, 2022 | $603.39K | -13.1% |
| FY2021 | Dec 31, 2021 | $694.29K | -6.0% |
| FY2020 | Dec 31, 2020 | $738.28K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $343.69K | -23.9% |
| Q1 FY2026 | Mar 31, 2026 | $373.55K | -12.6% |
| Q4 FY2025 | Dec 31, 2025 | $400.95K | -8.6% |
| Q3 FY2025 | Sep 30, 2025 | $424.34K | -14.2% |
| Q2 FY2025 | Jun 30, 2025 | $451.47K | -7.2% |
| Q1 FY2025 | Mar 31, 2025 | $427.60K | -15.8% |
| Q4 FY2024 | Dec 31, 2024 | $438.50K | -22.8% |
| Q3 FY2024 | Sep 30, 2024 | $494.41K | -9.2% |
| Q2 FY2024 | Jun 30, 2024 | $486.40K | -15.9% |
| Q1 FY2024 | Mar 31, 2024 | $507.68K | -13.6% |
| Q4 FY2023 | Dec 31, 2023 | $567.85K | -5.9% |
| Q3 FY2023 | Sep 30, 2023 | $544.22K | -7.0% |
| Q2 FY2023 | Jun 30, 2023 | $578.27K | -7.6% |
| Q1 FY2023 | Mar 31, 2023 | $587.50K | -9.3% |
| Q4 FY2022 | Dec 31, 2022 | $603.39K | -13.1% |
| Q3 FY2022 | Sep 30, 2022 | $585.28K | -17.2% |
| Q2 FY2022 | Jun 30, 2022 | $626.01K | -12.1% |
| Q1 FY2022 | Mar 31, 2022 | $647.51K | -10.4% |
| Q4 FY2021 | Dec 31, 2021 | $694.29K | -6.0% |
| Q3 FY2021 | Sep 30, 2021 | $706.81K | – |
| Q2 FY2021 | Jun 30, 2021 | $712.14K | – |
| Q1 FY2021 | Mar 31, 2021 | $722.54K | – |
| Q4 FY2020 | Dec 31, 2020 | $738.28K | – |
See a number that looks wrong?